2 months ago
A portion of a $400,000 CCRC entrance fee qualifies as prepaid medical care, deductible on Schedule A the year you write the check.
Only itemizers qualify, and just medical costs exceeding 7.5% of AGI reduce taxable income. Standard-deduction filers get nothing.
Pairing the entrance-fee payment year with a Roth conversion or large capital gains lets the medical deduction shelter substantial income.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
If you or a parent is about to write a six-figure check to move into a continuing care retirement community (a CCRC, meaning a campus that bundles independent living, ****** isted living, and skilled nursing under one contract), stop before you sign. A meaningful slice of that entrance fee (often on a $400,000 ticket) counts as prepaid medical care under federal tax law, and it is deductible on the return for the year you pay it. You do not have to wait until you actually use the health wing. This is the CCRC entrance fee medical deduction, and it is one of the largest one-year itemized deductions a retiree will ever see.
#ccrc #care #prepaid #write
Only itemizers qualify, and just medical costs exceeding 7.5% of AGI reduce taxable income. Standard-deduction filers get nothing.
Pairing the entrance-fee payment year with a Roth conversion or large capital gains lets the medical deduction shelter substantial income.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
If you or a parent is about to write a six-figure check to move into a continuing care retirement community (a CCRC, meaning a campus that bundles independent living, ****** isted living, and skilled nursing under one contract), stop before you sign. A meaningful slice of that entrance fee (often on a $400,000 ticket) counts as prepaid medical care under federal tax law, and it is deductible on the return for the year you pay it. You do not have to wait until you actually use the health wing. This is the CCRC entrance fee medical deduction, and it is one of the largest one-year itemized deductions a retiree will ever see.
#ccrc #care #prepaid #write
4 months ago
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Merck & Co., Inc. (NYSE:MRK) is one of the best weight loss drugs on this list.
TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its use to children and adolescents between 2 and 17 years old. The updated indication applies to pediatric patients who have completed their initial pneumococcal vaccination series and have chronic health conditions that increase their vulnerability to pneumococcal disease. With this authorization, Capvaxive becomes the only pneumococcal conjugate vaccine (PCV) in the United States specifically evaluated and approved for this patient group.
In another major operational breakthrough, on June 12, Merck & Co., Inc. (NYSE:MRK) announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA and KEYTRUDA QLEX, its anti-PD-1 therapies, in combination with WELIREG for the adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at an increased risk of recurrence after surgery. The approval marks the first use of WELIREG in earlier-stage ccRCC and the first authorization of a PD-1 and HIF-2α inhibitor combination therapy. The decision was supported by results from the Phase 3 LITESPARK-022 trial, which showed the combination reduced the risk of recurrence, metastasis, or death by 28% compared with KEYTRUDA plus placebo in eligible patients.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company expanding its obesity pipeline through early-stage GLP-1 and dual agonist therapies. While it lacks a marketed weight-loss drug, its metabolic research and strong pharmaceutical portfolio make it a potential long-term obesity market contender.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its use to children and adolescents between 2 and 17 years old. The updated indication applies to pediatric patients who have completed their initial pneumococcal vaccination series and have chronic health conditions that increase their vulnerability to pneumococcal disease. With this authorization, Capvaxive becomes the only pneumococcal conjugate vaccine (PCV) in the United States specifically evaluated and approved for this patient group.
In another major operational breakthrough, on June 12, Merck & Co., Inc. (NYSE:MRK) announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA and KEYTRUDA QLEX, its anti-PD-1 therapies, in combination with WELIREG for the adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at an increased risk of recurrence after surgery. The approval marks the first use of WELIREG in earlier-stage ccRCC and the first authorization of a PD-1 and HIF-2α inhibitor combination therapy. The decision was supported by results from the Phase 3 LITESPARK-022 trial, which showed the combination reduced the risk of recurrence, metastasis, or death by 28% compared with KEYTRUDA plus placebo in eligible patients.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company expanding its obesity pipeline through early-stage GLP-1 and dual agonist therapies. While it lacks a marketed weight-loss drug, its metabolic research and strong pharmaceutical portfolio make it a potential long-term obesity market contender.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
